Heather Oakervee

Publications (31) View all

• Article: Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma.

  Rakesh Popat, Lenushka Maharaj, Heather Oakervee, Jamie Cavenagh, Simon Joel
  British Journal of Haematology 10/2012; · 4.94 Impact Factor
• Article: Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD.

  F L Dignan, D Greenblatt, M Cox, J Cavenagh, H Oakervee, J F Apperley, A K Fielding, A Pagliuca, G Mufti, K Raj, D I Marks, P Amrolia, A Peniket, P Medd, M N Potter, B E Shaw, J J Scarisbrick
  [show abstract] [hide abstract]
  ABSTRACT: Extracorporeal photopheresis (ECP) has become a recognised treatment for steroid-refractory chronic GVHD (cGVHD), but the optimal frequency and duration of treatment are yet to be established. We report on 82 consecutive patients with mucocutaneous cGVHD who received a bimonthly regimen of ECP treatment for two consecutive days, which could be subsequently tapered to a monthly regimen depending on response. Patients were steroid-refractory, steroid-dependent or steroid-intolerant, and 29 (35%) had multiorgan involvement. The median duration of treatment was 330 days (42-987). The median number of ECP cycles was 15 (1.5-32). Response was assessed by clinical assessment and reduction in immunosuppression after 6 months. 69/82 (84%) had completed 6 months of ECP and 65/69 (94%) had ≥ 50% improvement in symptoms and signs of cGVHD. A total of 77% of patients who completed 6 months of ECP had a reduction in immunosuppression dose and 80% had decreased their steroid dose (27.5% stopped, 30% had ≥ 75% reduction, 17.5% had ≥ 50% reduction and 25% had <50% reduction). OS at 3 years from the start of ECP was 69%. This study reports the largest series of patients receiving bimonthly ECP treatment for cGVHD, and confirms that ECP allows successful reduction of immunosuppression.
  Bone marrow transplantation 09/2011; 47(6):824-30. · 3.00 Impact Factor
• Article: Frequency of leukemic initiating cells does not depend on the xenotransplantation model used.

  J Vargaftig, D C Taussig, E Griessinger, F Anjos-Afonso, T A Lister, J Cavenagh, H Oakervee, J Gribben, D Bonnet
  Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 09/2011; 26(4):858-60. · 8.30 Impact Factor
• Article: Nosocomial transmission of parainfluenza 3 virus in hematological patients characterized by molecular epidemiology.

  A V Lee, D F Bibby, H Oakervee, A Rohatiner, I Ushiro-Lumb, D A Clark, F M Mattes
  [show abstract] [hide abstract]
  ABSTRACT: We report an outbreak of parainfluenza 3 virus involving 17 hematology-oncology patients on 2 hospital wards. Sequence analysis of clinical samples confirmed homology of strains for 16/17 patients and 1 healthcare worker. Epidemiological analysis of the outbreak supported the molecular data with nosocomial transmission of the same genetic strain as the cause of the outbreak.
  Transplant Infectious Disease 04/2011; 13(4):433-7. · 2.22 Impact Factor
• Article: Re-transplantation after bortezomib-based therapy.

  Curly Morris, Gordon Cook, Matthew Streetly, Paul Kettle, Mary Drake, Michael Quinn, Jim Cavet, Jane Tighe, Majit Kazmi, John Ashcroft, Mark Cook, John Snowden, Ade Olujohungbe, Scott Marshall, Jane Conn, Heather Oakervee, Rakesh Popat, Jamie Cavenagh
  British Journal of Haematology 01/2011; 153(5):666-8. · 4.94 Impact Factor